| Fecha | Trimestre | Sesión | BPA (est → real) | Ingresos (est → reales) |
|---|---|---|---|---|
| 26 oct 2026Próximo | Q3 2026 | — | -3,46 | 1,51 B |
2 sept 2026
Incyte is transitioning from a Jakafi-centric model to a diversified, multi-franchise biotech with several late-stage pipeline assets. See why INCY stock is a Buy.
1 sept 2026
WILMINGTON, Del., September 01, 2026--Incyte to Present at Upcoming Investor Conferences
30 ago 2026
In a recent interview on CNBC’s Halftime Report, Josh Brown, CEO of Ritholtz Wealth Management, highlighted Incyte (NASDAQ: INCY) and Biogen (NASDAQ: BIIB) as two of his “Best Stocks in the Market.” Brown said he wanted to focus on stocks that had “nothing to do” with the AI and data-center spending theme. “We wanted to […]
Incyte (INCY) is back in focus following renewed attention on upcoming ESMO data for its KRAS G12D inhibitor, known as 734, which is being studied in combination with chemotherapy for pancreatic ductal adenocarcinoma. The renewed focus on Incyte comes after a strong run in the share price, with the latest close at US$124.37 and a 90 day share price return of 30.11%. That move sits within a broader trend where the year to date share price return is 22.63%, while total shareholder return over 1...
Incyte (NasdaqGS: INCY) is drawing attention as its KRAS G12D inhibitor '734 heads into new data presentations at ESMO, focused on pancreatic ductal adenocarcinoma. The upcoming ESMO readout is expected to support ongoing Phase 3 trials of '734 in pancreatic cancer, a disease area with high unmet medical need. Interest is heightened after a competitor recently received FDA approval for a therapy targeting a similar pathway in oncology. This spotlight on Incyte shows how much investor...
28 ago 2026
Incyte Corporation (NASDAQ:INCY) generated buzz on August 19 when RBC Capital highlighted upcoming ESMO data for its KRAS G12D inhibitor ‘734 in combination with mFOLFIRINOX and GemNabP. RBC noted that while prior data was too limited for firm conclusions, the update should look “very competitive” and support ongoing Phase 3 efforts in first-line pancreatic ductal […]
27 ago 2026
Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
INCYTE (INCY) passes Minervini Trend Template & High Growth screen with strong earnings, sales, RS 93. Setup score 6/10 means wait for better entry.
23 ago 2026
Prelude Therapeutics has rebounded 500% in 12 months after a $60M option deal with Incyte for its JAK2 inhibitor program. Read why PRLD stock is a Hold.
20 ago 2026
Incyte (NASDAQ:INCY) has outperformed the market over the past 20 years by 8.29% on an annualized basis producing an average annual return of 17.52%. Currently, Incyte has a market capitalization of $25.75 billion.
Canaccord Genuity analyst John Newman initiates coverage on Incyte (NASDAQ:INCY) with a Buy rating and announces Price Target of $152.
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Incyte (NASDAQ:INCY) with a Buy and maintains $150 price target.
18 ago 2026
While Incyte has outperformed the broader market over the past year, Wall Street analysts remain cautiously optimistic about the stock’s prospects.
17 ago 2026
Piper Sandler analyst Allison Bratzel maintains Incyte (NASDAQ:INCY) with a Overweight and raises the price target from $110 to $130.
Incyte (INCY) shows strong growth momentum with a clean technical setup, combining high earnings growth, positive ratings, and a breakout opportunity.
14 ago 2026
On July 20, Halozyme Therapeutics, Inc. (NASDAQ:HALO) and Incyte Corporation (NASDAQ:INCY) announced a global collaboration and licensing deal to develop a subcutaneous formulation of Incyte’s INCA033989. The first-in-class monoclonal antibody targets mutant calreticulin (mutCALR)-expressing myeloproliferative neoplasms. By utilizing Halozyme’s proprietary ENHANZE drug delivery technology, INCY aims to create a more convenient dosing regimen for patients. […]
12 ago 2026
Biopharmaceutical company Incyte Corporation (INCY) gets Big Money support to gain 23% so far in 2026.
7 ago 2026
WILMINGTON, Del., August 07, 2026--Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
